Regeneron drug highly effective for those who can't take statins: study

November 17, 2014 5:06 PM

16 0

CHICAGO (Reuters) - Regeneron Corp's experimental drug alirocumab helped 10 times as many high-risk patients unable to tolerate widely-used statins get their "bad" LDL cholesterol down to target levels than Merck & Co's Zetia, according to data from a clinical trial presented on Monday.

Alirocumab, developed along with French drugmaker Sanofi, belongs to a new class of potent drugs that block a naturally occurring protein called PCSK9 that prevents the liver from removing LDL from the blood.

Also read: Charles Barkley Blasts 'Dictator' Kim Jong-un, 'Treats People Like Crap'

Read more

To category page